Repetitive Assessement of PRECISE-DAPT Score

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Feb 19, 2019

Keywords

ClinConnect Summary

The RE-SCORE trial is a multicenter study aimed at comparing usual care of patients treated with PCI with a novel strategy of change of therapy during follow-up on the base of the Delta PRECISE-DAPT score, as assessed every 3 months in PCI patients receiving DAPT. The primary end-point of the study is the occurrence of bleeding, as defined according to the criteria of the Bleeding Academic Research Consortium (BARC). The second end-point is a composite of cardiac death, myocardial infarction, stroke, definite or probable stent thrombosis (ST), or BARC criteria type 2, 3 or 5 bleeding.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Consecutive patients undergoing percutaneous coronary intervention
• • Indication to dual antiplatelet therapy for at least 3 months
• Exclusion Criteria:
• • - Contraindications to dual antiplatelet therapy lasting more than 3 months